A non-purine selective xanthine oxidase inhibitor used for the chronic management of hyperuricemia in patients with gout. Febuxostat is indicated as a second-line urate-lowering agent when allopurinol is contraindicated, not tolerated, or fails to achieve target uric acid levels. It carries an FDA black box warning regarding increased cardiovascular death risk.
Evidence rating strong. Most-documented uses: potent reduction of serum uric acid, alternative for patients who cannot tolerate allopurinol, no dose adjustment needed for mild-to-moderate renal impairment. 10 sources indexed (2019–2025), with 3 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Selectively inhibits both the oxidized and reduced forms of xanthine oxidase, blocking the conversion of hypoxanthine to xanthine and xanthine to uric acid. Unlike allopurinol, febuxostat is a non-purine inhibitor and does not require activation by xanthine oxidase, resulting in more potent and sustained uric acid lowering.
Class
Xanthine Oxidase Inhibitor (Gout)
Dosing
Dosing & protocol.
Common range
40 mg once daily initially; may increase to 80 mg daily if uric acid not <6 mg/dL after 2 weeks (as prescribed by your physician)
Recommended form
Tablet
Can be taken with or without food; no significant food-drug interaction2
Safety
Full safety detail.
Side effects
Liver function abnormalities
Nausea
Arthralgia
Rash
Gout flare during initiation
Dizziness
Cardiovascular events (MI, stroke)
Contraindications
Concurrent use with azathioprine or mercaptopurine
Alcohol can undermine febuxostat therapy by increasing gout flare risk and raising urate pressure. Febuxostat lowers urate through xanthine oxidase inhibition, but alcohol can still trigger attacks, particularly during early urate-lowering therapy when flares are common. Spacing alcohol away from febuxostat does not prevent this problem.
Recommendation: Avoid heavy alcohol use while taking febuxostat. During the first months of therapy or during dose changes, keep alcohol intake as low as possible and follow the prescribed flare-prevention plan. Report persistent attacks so your prescriber can reassess serum urate and prophylaxis.
Vitamin C has a modest urate-lowering effect in randomized-trial meta-analyses, while febuxostat is a much stronger urate-lowering medicine. The combination may slightly support serum urate reduction, but Vitamin C is not a substitute for febuxostat and may not meaningfully prevent gout attacks by itself. High doses can cause gastrointestinal upset and may be inappropriate for people prone to kidney stones.
Recommendation: Do not replace febuxostat with Vitamin C. If you use Vitamin C, keep the dose moderate and tell your prescriber, especially if you have kidney stones, kidney disease, or persistent gout flares. Continue serum urate monitoring to confirm the treatment target is being reached.
High-dose Vitamin B3 products containing niacin or nicotinic acid can increase serum uric acid and precipitate gout. That effect can work against febuxostat's urate-lowering goal, particularly if urate is not yet at target. The risk is most relevant for high-dose niacin products, not normal dietary Vitamin B3 intake.
Recommendation: Do not add high-dose Vitamin B3 during febuxostat therapy without checking with your prescriber. If niacin is required, monitor serum urate after dose changes and report any increase in flares. Keep taking febuxostat as prescribed unless your clinician changes the plan.
Chen J, Zhang Y, Wang Y et al.. Comparative efficacy and safety of febuxostat and allopurinol in chronic kidney disease stage 3-5 patients with asymptomatic hyperuricemia: a network meta-analysis. Renal failure. 2025
Yang XH, Zhang BL, Cheng Y et al.. Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials. Annals of medicine. 2024
Guan X, Zhang S, Liu J et al.. Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis. Frontiers in pharmacology. 2022
Cuenca JA, Balda J, Palacio A et al.. Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis. International journal of rheumatology. 2019
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Febuxostat in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack